Ann Marie Navar1, Tracy Y Wang2, Anne C Goldberg3, Jennifer G Robinson4, Veronique L Roger5, Peter F Wilson6, Salim S Virani7, Joesph Elassal8, L Veronica Lee8, Laura E Webb2, Eric Peterson2. 1. Duke Clinical Research Institute, Durham, NC. Electronic address: navar006@mc.duke.edu. 2. Duke Clinical Research Institute, Durham, NC. 3. Washington University School of Medicine, St Louis, MO. 4. University of Iowa, Iowa City, IA. 5. Mayo Clinic, Rochester, MN. 6. Emory Clinical Cardiovascular Institute, Atlanta, GA. 7. Michael E. Debakey Veterans Affaris Hospital and Baylor College of Medicine, Houston, TX. 8. Regeneron Pharmaceuticals, Inc, Tarrytown, NY.
Abstract
BACKGROUND: Despite improvements in diagnosis and treatment, the prevalence of hyperlipidemia among adults in the United States remains high. Data are limited on treatment patterns and patient perceptions of cardiovascular disease risk since the release of new lipid guidelines. OBJECTIVES: The objectives of the PALM registry are to assess contemporary patterns of lipid-lowering therapy use among adults receiving care in a nationally representative cohort of community clinics, determine consistency of treatment with varying lipid guidelines, identify factors affecting use of lipid-lowering therapy including patient-reported statin intolerance, and assess patient and provider knowledge of cardiovascular risk reduction goals. STUDY DESIGN: The PALM registry will enroll 7,500 patients likely to be considered for lipid-lowering therapy from 175 cardiology, primary care, and endocrinology practices across the United States. In this cross-sectional, observational registry, a novel tablet-based platform will be used to collect patient-reported knowledge, attitudes, and beliefs regarding cardiovascular risk reduction and lipid management. Chart abstraction and core laboratory lipid levels will describe current lipid management. Provider surveys will assess perception of current lipid-lowering goals and barriers to optimal cardiovascular risk reduction. CONCLUSION: The PALM registry will allow for better understanding of current practice patterns, patient experiences, and patient and provider attitudes toward cholesterol management for cardiovascular disease risk reduction. These data can be used to better understand gaps in care and design targeted interventions to improve uptake of lipid-lowering therapies for cardiovascular risk reduction.
RCT Entities:
BACKGROUND: Despite improvements in diagnosis and treatment, the prevalence of hyperlipidemia among adults in the United States remains high. Data are limited on treatment patterns and patient perceptions of cardiovascular disease risk since the release of new lipid guidelines. OBJECTIVES: The objectives of the PALM registry are to assess contemporary patterns of lipid-lowering therapy use among adults receiving care in a nationally representative cohort of community clinics, determine consistency of treatment with varying lipid guidelines, identify factors affecting use of lipid-lowering therapy including patient-reported statin intolerance, and assess patient and provider knowledge of cardiovascular risk reduction goals. STUDY DESIGN: The PALM registry will enroll 7,500 patients likely to be considered for lipid-lowering therapy from 175 cardiology, primary care, and endocrinology practices across the United States. In this cross-sectional, observational registry, a novel tablet-based platform will be used to collect patient-reported knowledge, attitudes, and beliefs regarding cardiovascular risk reduction and lipid management. Chart abstraction and core laboratory lipid levels will describe current lipid management. Provider surveys will assess perception of current lipid-lowering goals and barriers to optimal cardiovascular risk reduction. CONCLUSION: The PALM registry will allow for better understanding of current practice patterns, patient experiences, and patient and provider attitudes toward cholesterol management for cardiovascular disease risk reduction. These data can be used to better understand gaps in care and design targeted interventions to improve uptake of lipid-lowering therapies for cardiovascular risk reduction.
Authors: Alexander C Fanaroff; Shuang Li; Laura E Webb; Vincent Miller; Ann Marie Navar; Eric D Peterson; Tracy Y Wang Journal: Circ Cardiovasc Qual Outcomes Date: 2018-04
Authors: Ann Marie Navar; Tracy Y Wang; Shuang Li; Jennifer G Robinson; Anne C Goldberg; Salim Virani; Veronique L Roger; Peter W F Wilson; Joseph Elassal; L Veronica Lee; Eric D Peterson Journal: Am Heart J Date: 2017-08-12 Impact factor: 4.749
Authors: Ann Marie Navar; Tracy Y Wang; Xiaojuan Mi; Jennifer G Robinson; Salim S Virani; Veronique L Roger; Peter W F Wilson; Anne C Goldberg; Eric D Peterson Journal: JAMA Cardiol Date: 2018-12-01 Impact factor: 14.676
Authors: Michael G Nanna; Tracy Y Wang; Qun Xiang; Anne C Goldberg; Jennifer G Robinson; Veronique L Roger; Salim S Virani; Peter W F Wilson; Michael J Louie; Andrew Koren; Zhuokai Li; Eric D Peterson; Ann Marie Navar Journal: Circ Cardiovasc Qual Outcomes Date: 2019-08-16
Authors: Ann Marie Navar; Eric D Peterson; Shuang Li; Jennifer G Robinson; Veronique L Roger; Anne C Goldberg; Salim Virani; Peter W F Wilson; Michael G Nanna; L Veronica Lee; Joseph Elassal; Tracy Y Wang Journal: Circ Cardiovasc Qual Outcomes Date: 2018-03
Authors: Angela Lowenstern; Shuang Li; Salim S Virani; Ann Marie Navar; Zhuokai Li; Jennifer G Robinson; Veronique L Roger; Anne C Goldberg; Andrew Koren; Michael J Louie; Eric D Peterson; Tracy Y Wang Journal: Am Heart J Date: 2020-04-30 Impact factor: 4.749
Authors: Michael G Nanna; Ann Marie Navar; Pearl Zakroysky; Qun Xiang; Anne C Goldberg; Jennifer Robinson; Veronique L Roger; Salim S Virani; Peter W F Wilson; Joseph Elassal; L Veronica Lee; Tracy Y Wang; Eric D Peterson Journal: JAMA Cardiol Date: 2018-08-01 Impact factor: 14.676
Authors: Angela Lowenstern; Ann Marie Navar; Shuang Li; Salim S Virani; Anne C Goldberg; Michael J Louie; L Veronica Lee; Eric D Peterson; Tracy Y Wang Journal: Am J Cardiol Date: 2019-01-04 Impact factor: 2.778
Authors: Ann Marie Navar; Tracy Y Wang; Shuang Li; Xiaojuan Mi; Zhuokai Li; Jennifer G Robinson; Salim S Virani; Eric D Peterson Journal: Circ Cardiovasc Qual Outcomes Date: 2021-01-13
Authors: Christopher P Cannon; James A de Lemos; Robert S Rosenson; Christie M Ballantyne; Yuyin Liu; Qi Gao; Tamara Palagashvilli; Shushama Alam; Katherine E Mues; Deepak L Bhatt; Mikhail N Kosiborod Journal: JAMA Cardiol Date: 2021-06-16 Impact factor: 14.676